<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01162239</url>
  </required_header>
  <id_info>
    <org_study_id>DA002538</org_study_id>
    <secondary_id>2R01DA002538</secondary_id>
    <secondary_id>11633</secondary_id>
    <nct_id>NCT01162239</nct_id>
  </id_info>
  <brief_title>Maintaining Nonsmoking</brief_title>
  <official_title>Maintaining Nonsmoking</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The research is based on a chronic disorder model of cigarette smoking which suggests that&#xD;
      long-term treatment targeted to prevent relapse may be useful. Based on this model, the&#xD;
      investigators have developed a relapse prevention treatment to intervene on five areas&#xD;
      important in relapse prevention, including fluctuating motivation, depression, withdrawal,&#xD;
      weight gain, and social support. This treatment protocol has produced high long-term&#xD;
      abstinence rates when implemented in a clinical research setting. The current study will&#xD;
      evaluate the treatment model when implemented in a medical outpatient setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will test a series of hypotheses comparing the efficacy of the relapse prevention&#xD;
      treatment to other extended treatments. All participants will be assessed at baseline on&#xD;
      demographics, smoking behaviors, nicotine dependence, depression, alcohol and other drug&#xD;
      history and problems, mood disturbance, treatment support, stress, health status, and&#xD;
      motivation for change. Participants will be randomly assigned to one of four treatment&#xD;
      conditions. All participants will receive 12 weeks of combined pharmacological treatment&#xD;
      (varenicline) and behavioral treatment (five individual counseling sessions). Following this&#xD;
      brief treatment, participants will be randomly assigned to one of four treatment protocols&#xD;
&#xD;
        1. Monthly Brief Contact or&#xD;
&#xD;
        2. Extended Non-Specific Behavioral Treatment or&#xD;
&#xD;
        3. Extended Relapse Prevention Treatment or&#xD;
&#xD;
        4. Extended Relapse Prevention Treatment + availability of varenicline treatment.&#xD;
&#xD;
      Each extended treatment protocol is 40 weeks in duration following the initial 12 weeks of&#xD;
      treatment.&#xD;
&#xD;
      All participants will be assessed at weeks 12, 24, 52, 64, and 104, on smoking as well as&#xD;
      other psychometric measures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2010</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Reported 7-day Point Prevalence Abstinence at Week 12</measure>
    <time_frame>12 weeks following treatment initiation</time_frame>
    <description>Point prevalent abstinence is defined as biochemically verified (confirmed carbon dioxide (CO) &lt; 8 parts per million (ppm)) self-reported abstinence from smoking cigarettes in the past 7 days. Smoking status was then categorized as either Abstinent or Not Abstinent.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Reported 7-day Point Prevalence Abstinence at Week 24</measure>
    <time_frame>24 weeks following treatment initiation</time_frame>
    <description>Point prevalent abstinence is defined as biochemically verified (confirmed carbon dioxide (CO) &lt; 8 ppm) self-reported abstinence from smoking cigarettes in the past 7 days. Smoking status was then categorized as either Abstinent or Not Abstinent.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Reported 7-day Point Prevalence Abstinence at Week 52</measure>
    <time_frame>52 weeks following treatment initiation</time_frame>
    <description>Point prevalent abstinence is defined as biochemically verified (confirmed carbon dioxide (CO) &lt; 8 ppm) self-reported abstinence from smoking cigarettes in the past 7 days. Smoking status was then categorized as either Abstinent or Not Abstinent.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Reported 7-day Point Prevalence Abstinence at Follow-up Week 64</measure>
    <time_frame>64 weeks following treatment initiation</time_frame>
    <description>Point prevalent abstinence is defined as biochemically verified (confirmed carbon dioxide (CO) &lt; 8 ppm) self-reported abstinence from smoking cigarettes in the past 7 days. Smoking status was then categorized as either Abstinent or Not Abstinent.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Reported 7-day Point Prevalence Abstinence at Follow-up Week 104</measure>
    <time_frame>104 weeks following treatment initiation</time_frame>
    <description>Point prevalent abstinence is defined as biochemically verified (confirmed carbon dioxide (CO) &lt; 8 ppm) self-reported abstinence from smoking cigarettes in the past 7 days. Smoking status was then categorized as either Abstinent or Not Abstinent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of Combined Extended vs Brief Treatment at Week 24</measure>
    <time_frame>24 weeks following treatment initiation</time_frame>
    <description>The three extended treatment programs were combined and compared to the Brief treatment, with extended treatments expected to produce significant higher CO corrected abstinence rates overall. Comparisons will be tested using Chi-Square analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Combined Extended vs Brief Treatment at Week 52</measure>
    <time_frame>52 weeks following treatment initiation</time_frame>
    <description>The three extended treatment programs were combined and compared to the Brief treatment, with extended treatments expected to produce significant higher CO corrected abstinence rates overall. Comparisons will be tested using Chi-Square analysis.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">216</enrollment>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>Extended Brief Contact</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following standard brief treatment, participants have monthly meetings with medical staff.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extended Health Education</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following standard treatment, participants receive monthly counseling with content based on a health education model.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extended Relapse Prevention plus varenicline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model plus access to ongoing medication treatment with varenicline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extended Relapse Prevention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid. Participants in the Extended Relapse Prevention plus varenicline will receive varenicline for up to 40 additional weeks.</description>
    <arm_group_label>Extended Brief Contact</arm_group_label>
    <arm_group_label>Extended Health Education</arm_group_label>
    <arm_group_label>Extended Relapse Prevention</arm_group_label>
    <arm_group_label>Extended Relapse Prevention plus varenicline</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Initial Individual counseling</intervention_name>
    <description>Five 90 minute individual counseling sessions to occur during the first 12 weeks of initial treatment.</description>
    <arm_group_label>Extended Brief Contact</arm_group_label>
    <arm_group_label>Extended Health Education</arm_group_label>
    <arm_group_label>Extended Relapse Prevention</arm_group_label>
    <arm_group_label>Extended Relapse Prevention plus varenicline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Check-ins with medical staff</intervention_name>
    <description>Monthly brief (10-15 minutes) meetings with medical staff.</description>
    <arm_group_label>Extended Brief Contact</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Extended Individual Counseling - Health Model</intervention_name>
    <description>Monthly counseling sessions across a nine month period with content based on a health education model. Each session is 30-45 minutes in duration.</description>
    <arm_group_label>Extended Health Education</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Extended Individual Counseling - Relapse Prevention Model</intervention_name>
    <description>Eleven individual counseling sessions across a nine month period with content based on a relapse prevention model. Each session is 30-45 minutes in duration.</description>
    <arm_group_label>Extended Relapse Prevention</arm_group_label>
    <arm_group_label>Extended Relapse Prevention plus varenicline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Must be smoking 5 or more cigarettes per day&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous history of bipolar/manic-depressive disorder&#xD;
&#xD;
          -  Current diagnosis of schizophrenia&#xD;
&#xD;
          -  Acute life threatening diseases&#xD;
&#xD;
          -  Evidence of alcohol or other drug abuse so severe that the patient is judged to be&#xD;
             potentially unable to comply with the protocol&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Individuals with out of normal range blood pressure, active angina, valve disease,&#xD;
             valve replacement, active cardiomyopathies, myocardial infarction or Coronary artery&#xD;
             bypass grafting (CABG) within one year, and Congestive heart failure (CHF)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Humfleet, Ph. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 14, 2010</study_first_submitted>
  <study_first_submitted_qc>July 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2010</study_first_posted>
  <results_first_submitted>October 19, 2020</results_first_submitted>
  <results_first_submitted_qc>October 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 12, 2020</results_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking</keyword>
  <keyword>Tobacco</keyword>
  <keyword>Nicotine</keyword>
  <keyword>Smoking cessation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from University of California, San Francisco medical clinics and the general community. Participants from the general community were recruited through flyers posted at various community health care organizations and social service agencies. Advertisements were placed in local newspapers and websites.</recruitment_details>
      <pre_assignment_details>Participants were stratified based on gender, age, site, and number of cigarettes smoked per day at baseline. Participants were then randomly assigned to one of four treatment conditions derived from a double blinded allocation list prepared by a statistician. Neither participant nor the therapist were unblinded to final treatment until Week 8.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Extended Brief Contact</title>
          <description>Following standard brief treatment, participants have monthly meetings with medical staff.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
Check-ins with medical staff: Monthly brief (10-15 minutes) meetings with medical staff.</description>
        </group>
        <group group_id="P2">
          <title>Extended Health Education</title>
          <description>Following standard treatment, participants receive monthly counseling with content based on a health education model.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
individual counseling: Eleven individual counseling sessions across a nine month period. Each session is 30-45 minutes in duration.</description>
        </group>
        <group group_id="P3">
          <title>Extended Relapse Prevention Plus Varenicline</title>
          <description>Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model plus access to ongoing medication treatment with varenicline.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
individual counseling: Eleven individual counseling sessions across a nine month period. Each session is 30-45 minutes in duration.</description>
        </group>
        <group group_id="P4">
          <title>Extended Relapse Prevention</title>
          <description>Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
individual counseling: Eleven individual counseling sessions across a nine month period. Each session is 30-45 minutes in duration.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 12</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="49"/>
                <participants group_id="P4" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 24</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="48"/>
                <participants group_id="P4" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 52</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="48"/>
                <participants group_id="P4" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="48"/>
                <participants group_id="P4" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extended Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Extended Brief Contact</title>
          <description>Following standard brief treatment, participants have monthly meetings with medical staff.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
Check-ins with medical staff: Monthly brief (10-15 minutes) meetings with medical staff.</description>
        </group>
        <group group_id="B2">
          <title>Extended Health Education</title>
          <description>Following standard treatment, participants receive monthly counseling with content based on a health education model.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
individual counseling: Eleven individual counseling sessions across a nine month period. Each session is 30-45 minutes in duration.</description>
        </group>
        <group group_id="B3">
          <title>Extended Relapse Prevention Plus Varenicline</title>
          <description>Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model plus access to ongoing medication treatment with varenicline.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
individual counseling: Eleven individual counseling sessions across a nine month period. Each session is 30-45 minutes in duration.</description>
        </group>
        <group group_id="B4">
          <title>Extended Relapse Prevention</title>
          <description>Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
individual counseling: Eleven individual counseling sessions across a nine month period. Each session is 30-45 minutes in duration.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="52"/>
            <count group_id="B4" value="55"/>
            <count group_id="B5" value="216"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.3" spread="10.8"/>
                    <measurement group_id="B2" value="53.8" spread="9.4"/>
                    <measurement group_id="B3" value="47.0" spread="11.6"/>
                    <measurement group_id="B4" value="47.3" spread="11.8"/>
                    <measurement group_id="B5" value="48.9" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="46"/>
                    <measurement group_id="B5" value="182"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="103"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of cigarettes smoked per day</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>10 or less cigarettes smoked per day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 - 22 cigarettes smoked per day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21 - 30 cigarettes smoked per day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>31 or more cigarettes smoked per day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Reported 7-day Point Prevalence Abstinence at Week 12</title>
        <description>Point prevalent abstinence is defined as biochemically verified (confirmed carbon dioxide (CO) &lt; 8 parts per million (ppm)) self-reported abstinence from smoking cigarettes in the past 7 days. Smoking status was then categorized as either Abstinent or Not Abstinent.</description>
        <time_frame>12 weeks following treatment initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Extended Brief Contact</title>
            <description>Following standard brief treatment, participants have monthly meetings with medical staff.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
Check-ins with medical staff: Monthly brief (10-15 minutes) meetings with medical staff.</description>
          </group>
          <group group_id="O2">
            <title>Extended Health Education</title>
            <description>Following standard treatment, participants receive monthly counseling with content based on a health education model.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
individual counseling: Eleven individual counseling sessions across a nine month period. Each session is 30-45 minutes in duration.</description>
          </group>
          <group group_id="O3">
            <title>Extended Relapse Prevention Plus Varenicline</title>
            <description>Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model plus access to ongoing medication treatment with varenicline.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
individual counseling: Eleven individual counseling sessions across a nine month period. Each session is 30-45 minutes in duration.</description>
          </group>
          <group group_id="O4">
            <title>Extended Relapse Prevention</title>
            <description>Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
individual counseling: Eleven individual counseling sessions across a nine month period. Each session is 30-45 minutes in duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Reported 7-day Point Prevalence Abstinence at Week 12</title>
          <description>Point prevalent abstinence is defined as biochemically verified (confirmed carbon dioxide (CO) &lt; 8 parts per million (ppm)) self-reported abstinence from smoking cigarettes in the past 7 days. Smoking status was then categorized as either Abstinent or Not Abstinent.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Reported 7-day Point Prevalence Abstinence at Week 24</title>
        <description>Point prevalent abstinence is defined as biochemically verified (confirmed carbon dioxide (CO) &lt; 8 ppm) self-reported abstinence from smoking cigarettes in the past 7 days. Smoking status was then categorized as either Abstinent or Not Abstinent.</description>
        <time_frame>24 weeks following treatment initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Extended Brief Contact</title>
            <description>Following standard brief treatment, participants have monthly meetings with medical staff.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
Check-ins with medical staff: Monthly brief (10-15 minutes) meetings with medical staff.</description>
          </group>
          <group group_id="O2">
            <title>Extended Health Education</title>
            <description>Following standard treatment, participants receive monthly counseling with content based on a health education model.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
individual counseling: Eleven individual counseling sessions across a nine month period. Each session is 30-45 minutes in duration.</description>
          </group>
          <group group_id="O3">
            <title>Extended Relapse Prevention Plus Varenicline</title>
            <description>Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model plus access to ongoing medication treatment with varenicline.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
individual counseling: Eleven individual counseling sessions across a nine month period. Each session is 30-45 minutes in duration.</description>
          </group>
          <group group_id="O4">
            <title>Extended Relapse Prevention</title>
            <description>Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
individual counseling: Eleven individual counseling sessions across a nine month period. Each session is 30-45 minutes in duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Reported 7-day Point Prevalence Abstinence at Week 24</title>
          <description>Point prevalent abstinence is defined as biochemically verified (confirmed carbon dioxide (CO) &lt; 8 ppm) self-reported abstinence from smoking cigarettes in the past 7 days. Smoking status was then categorized as either Abstinent or Not Abstinent.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Reported 7-day Point Prevalence Abstinence at Week 52</title>
        <description>Point prevalent abstinence is defined as biochemically verified (confirmed carbon dioxide (CO) &lt; 8 ppm) self-reported abstinence from smoking cigarettes in the past 7 days. Smoking status was then categorized as either Abstinent or Not Abstinent.</description>
        <time_frame>52 weeks following treatment initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Extended Brief Contact</title>
            <description>Following standard brief treatment, participants have monthly meetings with medical staff.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
Check-ins with medical staff: Monthly brief (10-15 minutes) meetings with medical staff.</description>
          </group>
          <group group_id="O2">
            <title>Extended Health Education</title>
            <description>Following standard treatment, participants receive monthly counseling with content based on a health education model.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
individual counseling: Eleven individual counseling sessions across a nine month period. Each session is 30-45 minutes in duration.</description>
          </group>
          <group group_id="O3">
            <title>Extended Relapse Prevention Plus Varenicline</title>
            <description>Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model plus access to ongoing medication treatment with varenicline.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
individual counseling: Eleven individual counseling sessions across a nine month period. Each session is 30-45 minutes in duration.</description>
          </group>
          <group group_id="O4">
            <title>Extended Relapse Prevention</title>
            <description>Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
individual counseling: Eleven individual counseling sessions across a nine month period. Each session is 30-45 minutes in duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Reported 7-day Point Prevalence Abstinence at Week 52</title>
          <description>Point prevalent abstinence is defined as biochemically verified (confirmed carbon dioxide (CO) &lt; 8 ppm) self-reported abstinence from smoking cigarettes in the past 7 days. Smoking status was then categorized as either Abstinent or Not Abstinent.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Reported 7-day Point Prevalence Abstinence at Follow-up Week 64</title>
        <description>Point prevalent abstinence is defined as biochemically verified (confirmed carbon dioxide (CO) &lt; 8 ppm) self-reported abstinence from smoking cigarettes in the past 7 days. Smoking status was then categorized as either Abstinent or Not Abstinent.</description>
        <time_frame>64 weeks following treatment initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Extended Brief Contact</title>
            <description>Following standard brief treatment, participants have monthly meetings with medical staff.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
Check-ins with medical staff: Monthly brief (10-15 minutes) meetings with medical staff.</description>
          </group>
          <group group_id="O2">
            <title>Extended Health Education</title>
            <description>Following standard treatment, participants receive monthly counseling with content based on a health education model.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
individual counseling: Eleven individual counseling sessions across a nine month period. Each session is 30-45 minutes in duration.</description>
          </group>
          <group group_id="O3">
            <title>Extended Relapse Prevention Plus Varenicline</title>
            <description>Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model plus access to ongoing medication treatment with varenicline.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
individual counseling: Eleven individual counseling sessions across a nine month period. Each session is 30-45 minutes in duration.</description>
          </group>
          <group group_id="O4">
            <title>Extended Relapse Prevention</title>
            <description>Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
individual counseling: Eleven individual counseling sessions across a nine month period. Each session is 30-45 minutes in duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Reported 7-day Point Prevalence Abstinence at Follow-up Week 64</title>
          <description>Point prevalent abstinence is defined as biochemically verified (confirmed carbon dioxide (CO) &lt; 8 ppm) self-reported abstinence from smoking cigarettes in the past 7 days. Smoking status was then categorized as either Abstinent or Not Abstinent.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Reported 7-day Point Prevalence Abstinence at Follow-up Week 104</title>
        <description>Point prevalent abstinence is defined as biochemically verified (confirmed carbon dioxide (CO) &lt; 8 ppm) self-reported abstinence from smoking cigarettes in the past 7 days. Smoking status was then categorized as either Abstinent or Not Abstinent.</description>
        <time_frame>104 weeks following treatment initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Extended Brief Contact</title>
            <description>Following standard brief treatment, participants have monthly meetings with medical staff.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
Check-ins with medical staff: Monthly brief (10-15 minutes) meetings with medical staff.</description>
          </group>
          <group group_id="O2">
            <title>Extended Health Education</title>
            <description>Following standard treatment, participants receive monthly counseling with content based on a health education model.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
individual counseling: Eleven individual counseling sessions across a nine month period. Each session is 30-45 minutes in duration.</description>
          </group>
          <group group_id="O3">
            <title>Extended Relapse Prevention Plus Varenicline</title>
            <description>Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model plus access to ongoing medication treatment with varenicline.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
individual counseling: Eleven individual counseling sessions across a nine month period. Each session is 30-45 minutes in duration.</description>
          </group>
          <group group_id="O4">
            <title>Extended Relapse Prevention</title>
            <description>Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
individual counseling: Eleven individual counseling sessions across a nine month period. Each session is 30-45 minutes in duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Reported 7-day Point Prevalence Abstinence at Follow-up Week 104</title>
          <description>Point prevalent abstinence is defined as biochemically verified (confirmed carbon dioxide (CO) &lt; 8 ppm) self-reported abstinence from smoking cigarettes in the past 7 days. Smoking status was then categorized as either Abstinent or Not Abstinent.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Combined Extended vs Brief Treatment at Week 24</title>
        <description>The three extended treatment programs were combined and compared to the Brief treatment, with extended treatments expected to produce significant higher CO corrected abstinence rates overall. Comparisons will be tested using Chi-Square analysis.</description>
        <time_frame>24 weeks following treatment initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Extended Brief Contact</title>
            <description>Following standard brief treatment, participants have monthly meetings with medical staff.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
Check-ins with medical staff: Monthly brief (10-15 minutes) meetings with medical staff.</description>
          </group>
          <group group_id="O2">
            <title>Combined Extended Treatments</title>
            <description>Patients in the extended treatments were offered the followint:&#xD;
Following standard treatment, participants receive monthly counseling with content based on a health education model.&#xD;
or&#xD;
Eleven individual counseling sessions across a nine month period plus Varenicline.Each session 30-45 minutes in duration with a focus on relapse prevention&#xD;
or&#xD;
Eleven individual counseling sessions across a nine month period. Each session 30-45 minutes in duration with a focus on relapse prevention</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Combined Extended vs Brief Treatment at Week 24</title>
          <description>The three extended treatment programs were combined and compared to the Brief treatment, with extended treatments expected to produce significant higher CO corrected abstinence rates overall. Comparisons will be tested using Chi-Square analysis.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.62</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Combined Extended vs Brief Treatment at Week 52</title>
        <description>The three extended treatment programs were combined and compared to the Brief treatment, with extended treatments expected to produce significant higher CO corrected abstinence rates overall. Comparisons will be tested using Chi-Square analysis.</description>
        <time_frame>52 weeks following treatment initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Extended Brief Contact</title>
            <description>Following standard brief treatment, participants have monthly meetings with medical staff.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
Check-ins with medical staff: Monthly brief (10-15 minutes) meetings with medical staff.</description>
          </group>
          <group group_id="O2">
            <title>Combined Extended Treatments</title>
            <description>Patients in the extended treatments were offered the followint:&#xD;
Following standard treatment, participants receive monthly counseling with content based on a health education model.&#xD;
or&#xD;
Eleven individual counseling sessions across a nine month period plus Varenicline.Each session 30-45 minutes in duration with a focus on relapse prevention&#xD;
or&#xD;
Eleven individual counseling sessions across a nine month period. Each session 30-45 minutes in duration with a focus on relapse prevention</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Combined Extended vs Brief Treatment at Week 52</title>
          <description>The three extended treatment programs were combined and compared to the Brief treatment, with extended treatments expected to produce significant higher CO corrected abstinence rates overall. Comparisons will be tested using Chi-Square analysis.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.91</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 104 weeks</time_frame>
      <desc>Only serious adverse events were collected for this study</desc>
      <group_list>
        <group group_id="E1">
          <title>Extended Brief Contact</title>
          <description>Following standard brief treatment, participants have monthly meetings with medical staff.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
Check-ins with medical staff: Monthly brief (10-15 minutes) meetings with medical staff.</description>
        </group>
        <group group_id="E2">
          <title>Extended Health Education</title>
          <description>Following standard treatment, participants receive monthly counseling with content based on a health education model.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
individual counseling: Eleven individual counseling sessions across a nine month period. Each session is 30-45 minutes in duration.</description>
        </group>
        <group group_id="E3">
          <title>Extended Relapse Prevention Plus Varenicline</title>
          <description>Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model plus access to ongoing medication treatment with varenicline.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
individual counseling: Eleven individual counseling sessions across a nine month period. Each session is 30-45 minutes in duration.</description>
        </group>
        <group group_id="E4">
          <title>Extended Relapse Prevention</title>
          <description>Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model.&#xD;
Varenicline: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.&#xD;
Individual counseling: Five 90 minute individual counseling sessions.&#xD;
individual counseling: Eleven individual counseling sessions across a nine month period. Each session is 30-45 minutes in duration.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Insect Bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Concentration Impariment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Gary Humfleet, PhD</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>(415) 476-7674</phone>
      <email>Gary.Humfleet@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

